BD Says Biosciences Revenue Jumps 9 Percent in Fiscal Q3 as R&D Spend Soars | GenomeWeb
NEW YORK (GenomeWeb News) – Becton Dickinson today said fiscal third-quarter revenue increased 7 percent as R&D costs soared 42 percent and income grew 9 percent.
 
Receipts for the three months ended June 30 increased to $1.5 billion from $1.4 billion year over year.
 
The BD Biosciences segment reported the strongest growth, as revenues increased 9 percent to $219 million. Sales of flow cytometry instruments, reagents, and cell imaging products contributed to the rise.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.